Cargando…
Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report
BACKGROUND: (Non-V600E) BRAF mutated colorectal cancer (CRC) is a rare disease entity with specific clinical features. These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often harbor a KRAS or NRAS mutation. Notably, median overall survival is lon...
Autores principales: | Callebout, Eduard, Ribeiro, Suzane Moura, Laurent, Stephanie, De Man, Marc, Ferdinande, Liesbeth, Claes, Kathleen B. M., Van der Meulen, Joni, Geboes, Karen P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560823/ https://www.ncbi.nlm.nih.gov/pubmed/31185985 http://dx.doi.org/10.1186/s12885-019-5763-5 |
Ejemplares similares
-
Focus on 16p13.3 Locus in Colon Cancer
por: Mampaey, Evi, et al.
Publicado: (2015) -
Complete radiological response to first-line regorafenib in a patient with
abdominal relapse of BRAF V600E mutated GIST
por: Nannini, Margherita, et al.
Publicado: (2020) -
Pathologic Assessment of Rectal Carcinoma after Neoadjuvant Radio(chemo)therapy: Prognostic Implications
por: Hav, Monirath, et al.
Publicado: (2015) -
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013) -
BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)